Formulation and Evaluation of Baclofen Nano-emulsion for the Treatment of Multiple Sclerosis

Abstract

In conclusion, the development and assessment of Baclofen nano-emulsion present a promising therapeutic avenue for addressing multiple sclerosis. This research aimed to fabricate and appraise the Nano-emulsion of Baclofen using the high-shear homogenization method. Various parameters such as Physical Appearance, pH, viscosity, % drug content, centrifugation, UV spectroscopy, and Fourier transform spectroscopy were evaluated to gauge the formulations' quality. Moreover, in vitro drug release studies and stability assessments were conducted. Formulation F5 exhibited a viscosity of 5920cp, and formulation F5 demonstrated the optimal drug release rate of 98.12% within 6 hours. Stability assessments revealed minor alterations in formulations after two months at 4°C ± 2 and 75% ± 5% humidity. These findings underscore the potential of nanoemulsions as a viable vehicle for orally administering Baclofen to treat sclerosis. Leveraging nanotechnology's advantages, this innovative formulation offers prospects for enhanced drug delivery, improved therapeutic efficacy, and mitigated adverse effects compared to conventional treatment modalities.